Amid years of enforcement discretion, the U.S. Food and Drug Administration (FDA) unveiled a proposed rule on October 3, 2023, outlining its plan to tighten regulatory oversight of laboratory developed tests (LDTs). Should the proposed rule be finalized without amendments, the FDA will supervise all LDTs as medical devices. Industry stakeholders have until December 4, 2023, to submit their comments on the proposal.
Published by Foley & Lardner LLP originally on JD Supra, the proposal signals a potential substantial shift in the regulation of LDTs. Previous years have witnessed the FDA exercising enforcement discretion in this area, a policy that may have allowed innovation and flexibility in certain sectors but that also left some questions around public safety and quality control unanswered.
This proposed overhaul is not without potential impacts. LDTs, which comprise tests that laboratories create and implement internally, could witness stringent controls akin to those imposed on medical devices if the proposal goes through. This could lead to a radical adjustment in their development, production, and utilization processes.
Furthermore, the FDA’s intent to extend its regulatory purview over all LDTs rather than exercising discretion case-by-case presents a significant departure from past practices. Determining what this proposed change signifies for laboratories and their developments, and anticipating potential challenges, should be a top concern for stakeholders in this space.
Comments and responses to the proposed rule could prove insightful as they may serve to indicate feedback from sector stakeholders and organizations whose operations and practices could be affected by this proposed change in policy. As discussions progress, it will be important for those engaged in this space to monitor updates and developments closely.